AbCellera Biologics Inc.

ABCLUnited States

24 filed reports · 364 financial concepts · 12 earnings calls

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

$75.1M

FY2025 · to Dec 31, 2025

up +161% vs $28.8M

10-K

Net income

-$146M

FY2025 · to Dec 31, 2025

a year earlier: -$163M

10-K

Operating income

-$217M

FY2025 · to Dec 31, 2025

a year earlier: -$315M

10-K

Latest quarter

Revenue

$10.6M

Q3 FY2026 · to Sep 30, 2026

up +18.8% vs $8.96M

10-Q

Net income

-$43.2M

Q1 FY2026 · to Mar 31, 2026

a year earlier: -$45.6M

10-Q

Operating income

-$53.3M

Q3 FY2026 · to Sep 30, 2026

a year earlier: -$76.3M

10-Q

Filed reports

24 reports · Jun 2021 to Sep 2026

Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 45 earnings-release figures, 47 commentary passages.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR172,468Jun 2021 to Sep 2026
Annual · 10-KSEC EDGAR52,194Dec 2021 to Dec 2025
Annual · 10-K/ASEC EDGAR11Dec 2021
Current · 8-KSEC EDGAR145Sep 2026

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q38-K2026-09-302026-11-0945Open
FY2026 Q310-Q2026-09-302026-11-09303Open
FY2026 Q210-Q2026-06-302026-08-05162Open
FY2026 Q110-Q2026-03-312026-05-11169Open
FY202510-K2025-12-312026-02-24699Open
FY2025 Q310-Q2025-09-302025-11-06144Open
FY2025 Q210-Q2025-06-302025-08-07125Open
FY2025 Q110-Q2025-03-312025-05-08124Open
FY202410-K2024-12-312025-02-27388Open
FY2024 Q310-Q2024-09-302024-11-04151Open
FY2024 Q210-Q2024-06-302024-08-06135Open
FY2024 Q110-Q2024-03-312024-05-07148Open

Financial data

364 concepts · 4,708 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial337 concepts · 4,528 facts · Dec 2019 to Sep 2026

  • Cash and cash equivalents at carrying value41 · Dec 2020 to Sep 2026
  • Stockholders equity (US GAAP)35 · Dec 2019 to Sep 2026
  • Adjustments to additional paid in capital sharebased compensation requisite service period recognition value34 · Dec 2019 to Sep 2026
  • Allocated share based compensation expense34 · Dec 2019 to Sep 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations34 · Dec 2019 to Sep 2026
  • Comprehensive income net of tax34 · Dec 2019 to Sep 2026
  • Contract with customer liability34 · Dec 2019 to Sep 2026
  • Contract with customer liability revenue recognized34 · Dec 2019 to Sep 2026
  • Depreciation34 · Dec 2019 to Sep 2026
  • Grants and incentives34 · Dec 2019 to Sep 2026
  • Income loss from continuing operations before income taxes extraordinary items noncontrolling interest34 · Dec 2019 to Sep 2026
  • Net income loss34 · Dec 2019 to Sep 2026
  • Net income loss available to common stockholders basic34 · Dec 2019 to Sep 2026
  • Net income loss available to common stockholders diluted34 · Dec 2019 to Sep 2026
  • Nonoperating income expense34 · Dec 2019 to Sep 2026
  • Operating expenses (US GAAP)34 · Dec 2019 to Sep 2026
  • Operating income loss34 · Dec 2019 to Sep 2026
  • Research and development expense34 · Dec 2019 to Sep 2026
  • Revenue34 · Dec 2019 to Sep 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect32 · Dec 2019 to Sep 2026
  • Increase decrease in deferred revenue32 · Dec 2019 to Sep 2026
  • Net cash provided by used in financing activities32 · Dec 2019 to Sep 2026
  • Net cash provided by used in investing activities32 · Dec 2019 to Sep 2026
  • Net cash provided by used in operating activities32 · Dec 2019 to Sep 2026

Product2 concepts · 116 facts · Dec 2019 to Sep 2026

  • Revenue112 · Dec 2019 to Sep 2026
  • Royalty Revenue4 · Dec 2020 to Dec 2023

KPI22 concepts · 44 facts · Sep 2025 to Sep 2026

  • Accounts payable and accrued liabilities2 · Sep 2025 to Sep 2026
  • Amortization of intangible assets2 · Sep 2025 to Sep 2026
  • Deferred grant income2 · Sep 2025 to Sep 2026
  • Deferred revenue2 · Sep 2025 to Sep 2026
  • Depreciation of property and equipment2 · Sep 2025 to Sep 2026
  • Income taxes receivable2 · Sep 2025 to Sep 2026
  • Increase (decrease) in cash and cash equivalents2 · Sep 2025 to Sep 2026
  • Investments in equity accounted investees2 · Dec 2025 to Sep 2026
  • Long-term investments and other assets2 · Sep 2025 to Sep 2026
  • Net cash provided by financing activities2 · Sep 2025 to Sep 2026
  • Net cash provided by (used in) investing activities2 · Sep 2025 to Sep 2026
  • Net cash provided by (used in) operating activities2 · Sep 2025 to Sep 2026
  • Net loss2 · Sep 2025 to Sep 2026
  • Other2 · Sep 2025 to Sep 2026
  • Other assets2 · Sep 2025 to Sep 2026
  • Proceeds from marketable securities2 · Sep 2025 to Sep 2026
  • Property and equipment in accounts payable2 · Sep 2025 to Sep 2026
  • Purchase of marketable securities2 · Sep 2025 to Sep 2026
  • Purchases of property and equipment2 · Sep 2025 to Sep 2026
  • Receipt of grant funding2 · Sep 2025 to Sep 2026
  • Research fees and grants receivable2 · Sep 2025 to Sep 2026
  • Stock-based compensation2 · Sep 2025 to Sep 2026

Geography3 concepts · 20 facts · Dec 2021 to Dec 2025

  • Revenue10 · Dec 2021 to Dec 2025
  • CANADA5 · Dec 2021 to Dec 2025
  • Other Foreign Countries5 · Dec 2021 to Dec 2025

Segments

136 facts

Figures broken down by business line, region, product or another axis the company reports on.

Product or service5 members · 116 facts

  • Research Fees34 · Dec 2019 to Sep 2026
  • Milestone Payments30 · Mar 2020 to Dec 2025
  • License25 · Mar 2021 to Dec 2025
  • Royalty21 · Dec 2020 to Dec 2024
  • Licensing And Royalty Revenue6 · Mar 2025 to Sep 2026

Statement geographical3 members · 20 facts

  • CA10 · Dec 2021 to Dec 2025
  • Other Foreign Countries5 · Dec 2021 to Dec 2025
  • US5 · Dec 2021 to Dec 2025

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

  • Earnings-release commentary12 claims from 1 report · Sep 2026
  • Management discussion (MD&A) commentary35 claims from 1 report · Sep 2026
  • Risk-factor changes99 claims from 3 reports · Dec 2022 to Dec 2024
  • Risk factors354 risks from 4 annual reports · 2021 to 2024

Earnings calls

12 calls · Feb 2024 to Nov 2026

Transcripts with management claims and analyst questions, one per fiscal period.

  • FY2026 Q32026-11-09
  • FY2026 Q22026-08-05
  • FY2026 Q12026-05-12
  • FY2025 Q42026-02-24
  • FY2025 Q32025-11-07
  • FY2025 Q22025-08-07
  • FY2025 Q12025-05-08
  • FY2024 Q42025-02-27
  • FY2024 Q32024-11-04
  • FY2024 Q22024-08-06
  • FY2024 Q12024-05-07
  • FY2023 Q42024-02-20

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of AbCellera Biologics Inc. (ABCL) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.

AbCellera Biologics Inc. (ABCL): FY2025 revenue $75.1M · FactIQ